Companion Segment to Bolster Veterinary Vaccines Market Growth During 2025-2031

According to our new research study on "Veterinary Vaccines Market Forecast to 2031 - Global Analysis - by Technology, Animal Type, Route Of Administration, End User," the market is expected to reach US$ 13.67 billion by 2031 from US$ 9.13 billion in 2024. The market is estimated to register a CAGR of 6.0% from 2025 to 2031. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the market growth.

Technological innovations are transforming the veterinary vaccine market, propelling vaccine development, delivery, and innovation in effectiveness. New technologies such as recombinant DNA technology, vector-based vaccines, and mRNA platforms are revolutionizing vaccines, providing protection against chronic or life-threatening diseases. Recombinant vaccines such as the Merial PUREVAX series for cats, do away with the necessity of live pathogens while offering good immunity, lessening the threat of adverse reactions. mRNA technology that became prominent over the recent past is being studied for veterinary purposes, with Elanco investing in research aimed at creating future-generation animal vaccines. Technological enhancements in the modes of vaccine delivery, including oral vaccines and needle-free injectors, are enhancing convenience and compliance among pet owners and livestock producers. For instance, the oral rabies vaccine of Boehringer Ingelheim has witnessed extensive usage within wildlife management initiatives, and such applications exemplify the prospects for new delivery methods.

Soaring Awareness Regarding Animal Health Is Propelling the Growth of Veterinary Vaccines Market

Over the past decade, there has been a shift in people's perception of animal health as a means of ensuring animal welfare and as a critical factor in public health, food security, and economic stability. The Food and Agriculture Organization (FAO) emphasizes that healthy livestock are essential for sustainable food systems, driving the adoption of vaccines to prevent foot-and-mouth disease, brucellosis, and avian influenza. Similarly, pet owners are becoming educated about the importance of preventive healthcare, such as vaccinations, to ensure their companion animals live longer, healthier lives. According to a 2022 survey by the American Veterinary Medical Association (AVMA), over 80% of pet owners in the US expressed a willingness to invest in regular vaccinations and check-ups for their pets, highlighting the growing prioritization of proactive animal healthcare.

The increasing availability of information on animal health through digital platforms, veterinary organizations, and public campaigns has empowered pet owners and farmers to learn about the risks of preventable diseases, including zoonotic ones such as rabies and leptospirosis, which can be transmitted from animals to humans. Organizations such as the WHO and the World Organization for Animal Health (WOAH) have launched global awareness campaigns emphasizing the role of vaccination in controlling zoonotic diseases. The WHO's Global Strategic Plan to End Human Deaths from Dog-Mediated Rabies by 2030 boosts initiatives to promote vaccine adoption on a large scale. The role of veterinarians as advocates for preventive care has also contributed to this growing awareness. Veterinarians play a proactive role in educating pet owners and livestock farmers about vaccine schedules, the benefits of immunization, and the risks of neglecting preventive care. The advancements in veterinary medicine, such as the development of combination vaccines, which simplify vaccine administration and improve compliance among animal owners further contribute to the awareness.

In conclusion, the growing awareness of animal health has driven the growth of the veterinary vaccines market. With governments, veterinarians, and global organizations working together to emphasize the importance of preventive care, the adoption of vaccines for companion animals and livestock has increased. This trend is expected to continue as more people recognize the interconnectedness of animal health, human health, and economic stability.

The veterinary vaccines market is segmented on the basis of technology, animal type, route of administration, end user, and geography. The veterinary vaccines market, based on technology, is segmented into live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, and others. The live attenuated vaccines held the largest share of the veterinary vaccines market in 2024, and it is expected to register a significant CAGR during 2025-2031.

By animal type, the market is categorized into companion, livestock, and poultry. The livestock and poultry segment held the largest share of the veterinary vaccines market in 2024. The companion animal segment is further divided into dogs, cats, horses, and others. The livestock and poultry segment is categorized into chicken, cattle, and others. The livestock sectors have undergone rapid changes in the past few years as the demand for animal-derived foods has increased significantly. According to the Food and Agriculture Organization (FAO), the global trade in meat and meat products was expected to reach 41.9 million tonnes in 2024, reflecting a 3.2 percent increase from 2023. As per the same source, cattle account for 81% of global milk production, followed by buffaloes at 15%. Goats, sheep, and camels contribute 2%, 1%, and 0.4% shares, respectively. The remaining share of milk production comes from other dairy species, such as equines and yaks. The rising global population contributes to the demand for meat, dairy, and other animal products, leading to intensified livestock farming. This intensification necessitates effective disease prevention measures to maintain animal health and productivity, driving up the demand for veterinary vaccines.

As per route of administration, the veterinary vaccines market is divided into intramuscular, subcutaneous, and others. The intramuscular segment held a larger share of the veterinary vaccines market in 2024, and it is expected to register a significant CAGR during 2025-2031.

In terms of geography, the veterinary vaccines market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the veterinary vaccines Market in 2024. The North America veterinary vaccines market is segmented into the US, Canada, and Mexico. North America captured a significant share of the global market. The growth of the market is driven by factors such as the growing launch of veterinary vaccines from market players, the increasing government support to provide cost-effective healthcare services, the rising strategic developments by the veterinary vaccine players to enhance services, and a growing healthcare industry that demands frameworks and guidelines based on real-world data for their business models. Livestock groups provide consumers with different products and services, including meat, milk, eggs, fiber, and draught power. Viral infection among livestock, companion animals, and others is a critical aspect of animal health in the US. The viruses infecting the animals spread at a faster rate. Thus, immunizations of the animal from such viruses are of prime importance in animal healthcare in the country. Foot-and-mouth disease is a highly contagious viral disease that affects cloven-hoofed animals, such as cattle, pigs, sheep, and goats. While the US has been free of FMD for decades, outbreaks in other parts of the world, particularly in regions with close international trade and animal transport, present an ongoing risk.

Boehringer Ingelheim International GmbH, Zoetis Inc, Merck & Co Inc, Virbac SA, Biovac LTD, Neogen Corp, Elanco Animal Health Inc, HIPRA SA, Ceva Sant